STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.
Professor Ellie Barnes (STOP-HCV lead) talks to the Oxford Centre for Personalised Medicine about the project.
The STOP-HCV consortium is formed of 17 partners representing academia, industry and the Hepatitis C Trust.
Read more about the science we've published.
Find out more about STOP-HCV from members of the STOP-HCV Consortium.
Lancet Commission on hepatitis elimination, led by Professor Graham Cooke, now available online.
Public Health England’s (PHE) Hepatitis C Virus Resistance Group publishes guidance on antiviral resistance testing in the management of hepatitis C.
"Diagnosis and research key to hepatitis elimination". Read this post by Professor John McLauchlan, written for the MRC Insight.
Extending STOP-HCV to S.E. Asia through recent awards from the MRC and the Wellcome Trust. Two recent awards will enable the consortium to extend its activities to Vietnam in S.E Asia
STOP-HCV genetic study - published in Nature Genetics (10 April 2017). Oxford University news describe the study which shows, for the first time, how the genetic make-up of HCV is influenced by its host.
STOP-HCV Cirrhosis Study reaches 1200 patient recruitment target. 1264 patients (recruited from over 30 hospital sites) are enrolled in the STOP-HCV Cirrhosis Study.
STOP-HCV Consortium publishes findings from its HCV next generation sequencing methods comparison exercise - available online at Journal of Clinical Microbiology.